Wire · opportunities
J&J Sells LAA Tech to Jaguar
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 18 September 2026 · Fusion42 review
Johnson & Johnson has exited the left atrial appendage (LAA) closure market by selling its Laminar technology to Jaguar LAA, a new private company formed with Santé Ventures and former Laminar management. The sale follows the suspension of a pivotal trial due to safety concerns and marks a strategic shift away from competing with established devices from Boston Scientific, Abbott, and Medtronic.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
You need to watch how Jaguar is advancing a distinct LAA closure method from a major player’s spinout, offering a route to compete where J&J paused. This deal opens a buying window if you build components or services for cardiovascular implant devices.
◆ Coverage
1 source · 18 Sep 2026
◆ Related on Wire
◆ Topics